The Brexit Timebomb: Expect Effects On Regulation, IP, R&D And Trade
This article was originally published in PharmAsia News
Executive Summary
June 24 was a seismic day, in more ways than one. The UK's decision to withdraw from the EU may have elated more than half of the voting public, but it has caused deep disappointment, anxiety and anger among many millions more in the UK, Europe and around the world. The move has broad implications for the pharma sector, including on Asian firms doing business in the UK.